(CercleFinance.com) – Oddo BHF reiterates its ‘outperformance’ opinion on Moderna with a price target raised from 118 to 126 dollars, ‘seeing the clinical, regulatory and commercial risk/reward as positive’ for the biotechnology company specializing in messenger RNA.
Following results for the first quarter of 2024 that exceeded expectations with confirmed annual targets, the research office took the opportunity to marginally adjust its expectations and integrate the latest market parameters into its price target.
‘The next launch will be against the respiratory syncytial virus planned for 2024. We believe that this launch should reassure investors who will no longer see Moderna as an essentially Covid 19 player,’ adds the analyst.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
